InvestorsHub Logo
Followers 829
Posts 119605
Boards Moderated 14
Alias Born 09/05/2002

Re: None

Monday, 03/21/2022 5:47:34 PM

Monday, March 21, 2022 5:47:34 PM

Post# of 867
FDA approves Keytruda monotherapy for recurrent endometrial cancer with MSI-H or dMMR:

https://finance.yahoo.com/news/fda-approves-merck-keytruda-pembrolizumab-203000436.html

The approval is based on ORR from single-arm cohorts of the KEYNOTE-158 trial.

Note: Keytruda plus Lenvima is already FDA-approved in the same setting for patients without either MSI-H or dMMR.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent MRK News